1. A drive shaft and piston assembly of a split-cycle four-stroke engine comprising:
a rotary drive shaft;
a plurality of circular eccentrics mounted on the aforementioned rotary drive shaft by means of indexing openings;
a plurality of pistons the number of which corresponds to the number of the circular eccentrics;
and connecting rods the number of which corresponds to the number of circular eccentrics and pistons, the connecting rods having one ends and other ends, the aforementioned one ends being pivotally connected to the respective circular eccentrics, and the aforementioned other ends being pivotally connected to the respective pistons, wherein the circular eccentrics being angularly shifted with respect to each other on the aforementioned rotary drive shaft at a phase angle that is in the range of 5\xb0 to 60\xb0, and wherein the aforementioned indexing openings have means for changing angular positions of the circular eccentrics with respect to each other on the rotary drive shaft in the range of the aforementioned phase angle.
2. The drive shaft and piston assembly of claim 1, wherein the indexing openings have cross-sections that exclude rotation of the circular eccentrics relative to the rotary drive shaft.
3. The drive shaft and piston assembly of claim 1, wherein the aforementioned assembly comprises at least one pair of sub-assemblies, each pair comprising a first sub-assembly and a second sub-assembly, each sub-assembly comprising a circular eccentric mounted on the rotary drive shaft, a piston, and a connecting rod pivotally connected to the circular eccentric and to the piston.
4. The drive shaft and piston assembly of claim 3, wherein the piston of the first sub-assembly of the aforementioned pair is a power piston and the piston of the second sub-assembly of the aforementioned pair is a compression piston.
5. The drive shaft and piston assembly of claim 1, wherein each circular eccentric is provided with a counterweight for balancing the assembly in order to tune an engine by reducing vibration and stress.
6. A method of optimization of a phase angle in a split-cycle four-stroke engine comprising the steps of:
providing a rotary drive shaft and a plurality of circular eccentrics;
removably mounting the circular eccentrics on the rotary drive shaft in a plurality of the first angular positions with respect to each other by means of indexing openings in the range of a phase angle;
testing the performance of the split-cycle four-stroke engine;
removing the circular eccentrics from the rotary drive shaft;
removably mounting the circular eccentrics in a second angular position with respect to each other which are different from the first angular positions;
testing the performance of the split-cycle four-stroke engine;
repeating the steps of removing, removably mounting, and testing a plurality of times; and finding the angular positions of the circular eccentrics which provide the best performance of the split-cycle four-stroke engine; and
creating a pre-production prototype of the split-cycle four-stroke engine based on the aforementioned finding.
7. The method of claim 6, wherein the phase angle is in the range of 5\xb0 to 60\xb0.
8. The method of claim 7, wherein the aforementioned indexing openings have means for changing angular positions of the eccentrics with respect to each other on the rotary drive shaft in the range of the aforementioned phase angle.
9. The method of claim 6, further comprising a step of balancing the assembly in order to tune an engine by providing each circular eccentric with a counterweight.
10. The method of claim 8, further comprising a step of balancing the assembly in order to tune an engine by providing each circular eccentric with a counterweight.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for processing human placental cell sample, characterized in that said method comprises steps as follows:
a. collecting human term placenta tissue, and protecting the tissue in DMEM containing 0.5% to 5%, preferably 1% of human cord blood serum;
b. isolating human placental amniotic and chorionic mersenchymal stromal cells from the placenta tissue obtained in step a;
c. in vitro expanding said human placental cells in a cell culture system that is free of any component of animal origin, and preferably said culture system is a DMEM-based medium, which further includes:
1). 5%-30%, preferably 10%-20% of human cord blood serum; and
2). 1% of penicillinstreptomycin solution;
d. determining antigen type (HLA-typing) of major histocompatibility (MHC) of the placental cells from each cell donor;
e. bar-coding the various HLA-typed cells obtained in step d and integrating HLA type information to registry information data for each cell donor;
f. preserving said placental mersenchymal stromal cells in cryopreservating solution and storing said cells in liquid nitrogen, and preferably, said cryopreservating solution is consisted of 50% human cord blood serum or autologous cord blood serum, 40% DMEM and 10% dimethyl sulphoxide (DMSO).
2. The method according to claim 1, characterized in that the human cord blood serum used in said method is autologous cord blood serum which is obtained from autologous cord blood of the given placental mersenchymal stromal cell donor, therefore, said autologous cord blood serum and the placental mersenchymal stromal cells cultured with said serum are from the same donor.
3. The method according to claim 1, characterized in that: the antigen type in step d is determined using a testing kit, and preferably but not exclusively, said testing kit is a PCR-based testing kit; andor bar codes of the various HLA-typed cells in step e are generated using an automatic digital bar-coding system, and preferably but not exclusively, said digital bar-coding system is Brady bar coding system TSL2200 (Brady, the United States).
4. Human placental mersenchymal stromal cells obtained using the method according to claim 1.
5. The human placental mersenchymal stromal cell bank, characterized in that placental mersenchymal stromal cells from each donor in said human placental mersenchymal stromal cell bank are obtained using the method according to claim 1.
6. A method for banking human placental mersenchymal stromal cells, characterized in that said method comprises:
1) processing human placental mersenchymal stromal cell sample of each person using the method according to claim 1;
2) establishing searchable record of cell information, and said record of cell information is a program for registering and managing bar-coding information and information of banked cells in a computer-based program which allows the bank content to be searched by both donor identification (ID) and HLA type.
7. The method for banking human placental mersenchymal stromal cells according to claim 6, characterized in that said searchable record of cell information includes:
a. searching entries: (1) donor identification (ID) and (2) HLA type;
b. donor information: (1) donor’s name, address, and phone number of donor’s parents, (2) donor’s birth date and gender, (3) delivery hospital; and
c. banking information: (1) name of the person who certifies the cells for banking, (2) number of cells in each storage vial, number of vials stored, and location where each vial is stored, including building name, room number, liquid nitrogen tank number, rack number, cryopreservating box number, and position in the box.
8. The method for searching human placental cell sample in said human placental cell bank according to claim 5, said method comprising:
1) setting record of registry information for each sample, of which the content includes:
a. searching entries: (1) donor ID, (2) HLA type;
b. donor information: (1) donor’s name, address, and phone number of donor’s parents, (2) donor’s birth date and gender, (3) delivery hospital; and
c. banking information: (1) name of the person who certifies the cells for banking, (2) number of cells in each storage vial, number of vials stored, and location where each vial is stored, including building name, room number, liquid nitrogen tank number, rack number, cryopreservating box number, and position in the box;
2) requests of donor’s parents for determining whether to make searching information available to the public; and
3) searching engine that is capable of searching the bank content using each andor all of the searching entries respectively, and preferably but not exclusively, said searching engine is Tiger business management software (HD Tiger, China).
9. A method for preparing autologous cord blood serum, and preferably said autologous cord blood serum is used as a component of medium for expanding placental mersenchymal stromal cells, wherein said method comprises steps as follows:
a. inserting the needle of a clinic syringe into the umbilical vein at the time of birth and taking the cord blood from the vein into the syringe;
b. transferring the blood to a 50 ml centrifuge tube that is free of anticoagulants;
c. allowing the blood to clot at 37\xb0 C. for 30 to 60 minutes;
d. cooling the clotted blood at 0 to 5\xb0 C. for 15 to 45 minutes;
e. having the blood centrifuged at 1000 g for 10 minutes; and
f. transferring the serum to a collecting tube and incubating the serum at 50 to 56 for 30 minutes.
10. The use of human placental cells obtained using the method according to claim 1 or human placental cell bank established using the method according to claim 6 in treating human dysfunction and diseases due to cell injury or cell malfunction, and preferably, said human dysfunction and disease due to cell injury or cell malfunction is selected from the group consisting of Type I diabetes, neural injury, myocardial injury, Alzheimer’s disease and Parkinson’s Disease.
11. A method for treating human dysfunction and diseases due to cell injury or cell malfunction, said method comprising: using human placental cells obtained by the method according claim 1 or human placental cell bank established by the method according to claim 6, wherein preferably said human dysfunction and disease due to cell injury or cell malfunction is selected from the group consisting of Type I diabetes, neural injury, myocardial injury, Alzheimer’s disease and Parkinson’s Disease.